5-[[2-(4-methyl-1-piperazinyl)phenyl]methylene]-2,4-thiazolidinedione | 1203800-23-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 5-[[2-(4-methyl-1-piperazinyl)phenyl]methylene]-2,4-thiazolidinedione
• 英文别名: (5Z)-5-[2-(4-methylpiperazin-1-yl)benzylidene]-1,3-thiazolidine-2,4-dione；(5Z)-5-[[2-(4-methylpiperazin-1-yl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione
• CAS: 1203800-23-0
• 化学式: C₁₅H₁₇N₃O₂S
• 分子量: 303.385
• InChiKey: CWZULMCFFVJFEY-RAXLEYEMSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  78
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] QUINOLINE DERIVATIVES<br/>[FR] DERIVES QUINOLINIQUES
  申请人：PFIZER PROD INC

  公开号：WO2004043929A1

  公开（公告）日：2004-05-27

  The present invention relates to compounds of Formula I, wherein R1, R2, R3, R4, and n are as defined, and to pharmaceutically acceptable salts of said compounds. Compounds of Formula I have activity in agonizing 5HT7 receptors and are useful in treating, for example, disorders that can be treated by modulating circadian rhythms.

  本发明涉及式I的化合物，其中R1、R2、R3、R4和n如定义所述，并且涉及所述化合物的药用可接受的盐。式I的化合物在激活5HT7受体方面具有活性，并且可用于治疗例如可以通过调节昼夜节律来治疗的疾病。
• CHEMICAL COMPOUNDS 251
  申请人：Dakin Leslie

  公开号：US20110218182A1

  公开（公告）日：2011-09-08

  The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.

  该发明涉及化学式(I)的化合物及其盐。在某些实施例中，该发明涉及PIM-1和/或PIM-2以及/或PIM-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文披露的化合物的药物组合物，以及它们在预防和治疗PIM激酶相关疾病和疾病，特别是癌症中的用途。
• Aralkyl and aralkylidene heterocyclic lactams and imides
  申请人：——

  公开号：US20020049214A1

  公开（公告）日：2002-04-25

  The present invention relates to compounds of the formula I 1 wherein R 1 , R 2 , R 3 , X, Y and the dashed line are as defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use as psychotherapeutic agents.

  本发明涉及公式I1中的化合物，其中R1、R2、R3、X、Y和虚线如规范中所定义，以及用于它们制备的中间体，含有它们的药物组合物以及它们作为精神治疗剂的药用。
• ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES
  申请人：Pfizer Inc.

  公开号：US20020091117A1

  公开（公告）日：2002-07-11

  The present invention relates to compounds of the formula 1 wherein R 1 , R 2 , R 3 , X, Y and the dashed line are defined as in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. These compounds are useful as psychotherapeutic agents.

  本发明涉及公式1的化合物，其中R1、R2、R3、X、Y和虚线在说明书中有定义，以及其制备的中间体，含有它们的制药组合物和它们的药用用途。这些化合物可用作心理治疗剂。
• Chemical Compounds 251
  申请人：AstraZeneca AB

  公开号：US20150051185A1

  公开（公告）日：2015-02-19

  The invention relates to chemical compounds of formula I, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.

  本发明涉及公式I的化合物及其盐。在某些实施例中，本发明涉及PIM-1和/或PIM-2，以及/或PIM-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，本发明涉及包含本文所披露的化合物的制药组合物，以及它们在预防和治疗PIM激酶相关的疾病和状况，尤其是癌症方面的应用。